1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Asthma Partnering 2010-2015

Asthma Partnering 2010-2015

  • May 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

Summary
The Asthma Partnering 2010-2015 report provides understanding and access to the asthma partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Asthma Partnering 2009-2014 report provides understanding and access to the asthma partnering deals and agreements entered into by the worlds leading healthcare companies.

•Trends in asthma partnering deals
•Top asthma deals by value
•Deals listed by company A-Z, industry sector, stage of development, technology type

The Asthma Partnering 2009-2014 provides understanding and access to the asthma partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of asthma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors asthma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 120 links to online copies of actual asthma deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of asthma partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in asthma partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading asthma deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of asthma partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of asthma technologies and products.

Report scope

Asthma Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to asthma trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

•Trends in asthma dealmaking in the biopharma industry since 2009
•Access to summary headline, upfront, milestone and royalty data
•The leading asthma deals by value since 2009

In Asthma Partnering 2009-2014, the available deals are listed by:

•Headline value
•Upfront payment value
•Royalty rate value
•Company A-Z
•Industry sector
•Stage of development at signing
•Deal component type
•Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Benefits

Asthma Partnering 2009-2014 provides the reader with the following key benefits:


•In-depth understanding of asthma deal trends since 2009
•Access to summary headline, upfront, milestone and royalty data
•Comprehensive access to over 120 actual asthma deals entered into by the world’s biopharma companies since 2009
•Insight into key deal terms included in contracts, where disclosed
•Understand the key deal terms companies have agreed in deals
•Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Keywords

asthma, respiratory, partnering, licensing, deals, alliances, merger and acquisition, M&A, big pharma

Table Of Contents

Asthma Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asthma partnering

2.1. Introduction
2.2. Asthma partnering over the years
2.3. Big pharma asthma dealmaking activity
2.4. Big biotech asthma dealmaking activity
2.5. Most active asthma dealmakers
2.6. Asthma partnering by deal type
2.7. Asthma partnering industry sector
2.8. Asthma partnering by stage of development
2.9. Asthma partnering by technology type
2.10. Disclosed financial deal terms for asthma
2.10.1 Asthma headline values
2.10.2 Asthma upfront payments
2.10.3 Asthma milestone payments
2.10.4 Asthma royalty rates

Chapter 3 - Leading asthma deals

3.1. Introduction
3.2. Top asthma deals by value

Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Asthma partnering since 2009
Figure 2: Big pharma - top 50 - asthma deals 2009 to 2014
Figure 3: Big pharma asthma deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - asthma deals 2009 to 2014
Figure 5: Big biotech asthma deal frequency - 2009 to 2014
Figure 6: Asthma dealmaking activity- 2009 to 2014
Figure 7: Asthma partnering by deal type since 2009
Figure 8: Asthma partnering by industry sector since 2009
Figure 9: Asthma partnering by stage of development since 2009
Figure 10: Asthma partnering by technology type since 2009
Figure 11: Asthma deals with a headline value
Figure 12: Asthma deals with upfront payment values
Figure 13: Asthma deals with milestone payments
Figure 14: Asthma deals with royalty rates, %
Figure 15: Top asthma deals by value since 2009
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Epiomic Epidemiology Series: Asthma Forecast in 8 Major Markets 2016-2026

Epiomic Epidemiology Series: Asthma Forecast in 8 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • August 2016
  • by Black Swan Analysis Ltd132

Asthma is a chronic disease involving airway inflammation, reversible airflow obstruction, and bronchial hyper-responsiveness. The condition is usually triggered by environmental factors of which the symptoms ...

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

  • $ 4995
  • Industry report
  • August 2016
  • by GBI Research

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way Summary The respiratory therapy ...


Download Unlimited Documents from Trusted Public Sources

Pollution Control Industry in the US

  • November 2016
    5 pages
  • Pollution Contr...  

  • United States  

View report >

Healthcare Industry in Ireland

  • November 2016
  • Chronic Disease  

    Respiratory Dis...  

  • Ireland  

View report >

Asthma Statistics in Europe

  • November 2016
    10 pages
  • Asthma  

    Respiratory Dis...  

  • Europe  

    Germany  

View report >

Related Market Segments :

Asthma

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.